Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are independently associated with shorter TTR, SAR, and OS in patients with MSS, but not MSI, tumors.
Abstract: Background: The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/− cetuximab in two adjuvant therapy trials.
Methods: Three groups were defined: BRAF Mutant, KRAS Mutant, and double wild-type. The analytic strategy involved estimation of study-specific effects, assessment of homogeneity of results, and then analysis of pooled data as no differences in patient outcome were found between treatment arms in both trials. Associations of mutations with patient outcome were analyzed, and multivariable models were adjusted for treatment and relevant factors.
Results: Four thousand four hundred eleven tumors were evaluable for BRAF and KRAS mutations and mismatch repair status; 3934 were MSS and 477 were MSI. In MSS patients, all BRAF V600E mutations (hazard ratio [HR] = 1.54, 95% confidence interval [CI] = 1.23 to 1.92, P < .001), KRAS codon 12 alterations, and p.G13D mutations (HR = 1.60, 95% CI = 1.40 to 1.83, P < .001) were associated with shorter time to recurrence (TTR) and shorter survival after relapse (SAR; HR = 3.02 , 95% CI = 2.32 to 3.93, P < .001, and HR = 1.20, 95% CI = 1.01 to 1.44, P = .04, respectively). Overall survival (OS) in MSS patients was poorer for BRAF-mutant patients (HR = 2.01, 95% CI = 1.56 to 2.57, P < .001) and KRAS-mutant patients (HR = 1.62, 95% CI = 1.38 to 1.91, P < .001) vs wild-type. No prognostic role of KRAS or BRAF mutations was seen in MSI patients. Furthermore, no interaction was found between treatment arm (with or without cetuximab) and KRAS and BRAF mutations for TTR or OS in MSS patients.
Conclusions: In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are independently associated with shorter TTR, SAR, and OS in patients with MSS, but not MSI, tumors. Future clinical trials in the adjuvant setting should consider these mutations as important stratification factors.
201 citations
••
Centro Nacional de Investigaciones Cardiovasculares1, Aristotle University of Thessaloniki2, National Institutes of Health3, Lund University4, Leiden University Medical Center5, Golden Jubilee National Hospital6, University of Bristol7, French Institute of Health and Medical Research8, University of Leeds9, University of California, Los Angeles10, Icahn School of Medicine at Mount Sinai11, McGill University12, Hebron University13, National University of Singapore14, Duke University15, ETH Zurich16, University of Virginia Health System17, Philips18
TL;DR: The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes.
200 citations
••
TL;DR: It was concluded that where EGFR inhibitor-related acne-like rash and dermatitis coexist within irradiated fields, management should be based on the grade of dermatitis: for grade 1 (or no dermatitis), treatment recommendations for EGFR-related dermatitis outside irradiation fields should be followed.
200 citations
••
Humanitas University1, University of Cartagena2, University of Genoa3, Hebron University4, University of Veterinary Medicine Vienna5, University of Helsinki6, Autonomous University of Barcelona7, University of Montpellier8, University of Paris9, Erasmus University Rotterdam10, Universidad Autónoma de Nuevo León11, Mayo Clinic12, Kırıkkale University13, University of São Paulo14, University of South Florida15, San Juan de Dios Educational Foundation16, University of Marburg17, Nippon Medical School18, Federal University of Paraná19, University of Missouri–Kansas City20, Royal Children's Hospital21, Tan Tock Seng Hospital22, Medical University of Vienna23, I.M. Sechenov First Moscow State Medical University24, Johns Hopkins University School of Medicine25, Charité26
TL;DR: A thorough and updated critical appraisal of the most frequently used diagnostic tests, both in vivo and in vitro, and discusses skin tests, challenges, and serological and cellular in vitro tests, and provides an overview of indications, advantages and disadvantages of each in conditions such as respiratory, food, venom, drug, and occupational allergy.
199 citations
••
Katholieke Universiteit Leuven1, University of Ioannina2, Kyushu University3, Tongji University4, University of Ulsan5, University of Malaya6, National Taiwan University7, Peking University8, Yonsei University9, Hospital Kuala Lumpur10, National Health Research Institutes11, Kindai University12, Seconda Università degli Studi di Napoli13, University of Cambridge14, Kobe University15, Hebron University16
TL;DR: These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS).
199 citations
Authors
Showing all 2723 results
Name | H-index | Papers | Citations |
---|---|---|---|
José Baselga | 156 | 707 | 122498 |
M. I. Martínez | 134 | 1251 | 79885 |
Josep Tabernero | 111 | 803 | 68982 |
Jordi Rello | 103 | 694 | 35994 |
Xavier Montalban | 95 | 762 | 52842 |
James M. Downey | 91 | 381 | 29506 |
Enriqueta Felip | 83 | 622 | 53364 |
Joaquim Bellmunt | 82 | 660 | 41472 |
Joan Montaner | 80 | 489 | 22413 |
Marc Miravitlles | 76 | 651 | 25671 |
David H. Salat | 75 | 241 | 36779 |
Eduard Gratacós | 75 | 531 | 20178 |
Alex Rovira | 74 | 356 | 19586 |
Ramon Bataller | 72 | 283 | 19316 |
Maria Buti | 71 | 493 | 26596 |